Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

NET 40Endocrine 40Gastrointestinal 4CNS 4Sarcoma 1Dermatologic 1

Conditions

Paraganglioma 6Meningioma 6Pheochromocytoma 5Neuroendocrine Tumors 4Neuroblastoma 3Medulloblastoma 2Glioma 2Glioblastoma 2Ependymoma 2Sarcoma, Synovial 1Recurrence 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Hypertension 1Gastro-enteropancreatic neuroendocrine tumor 1Esthesioneuroblastoma, Olfactory 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Medullary 1Adrenal Gland Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 7gallium Ga 68 dotatate 6lutetium Lu 177 dotatate 4Fluorodeoxyglucose F18 33-Iodobenzylguanidine 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3fluorodopa F 18 2Specimen Handling 2FAPI-46 2Everolimus 2Erlotinib Hydrochloride 2vandetanib 1romidepsin 1pertuzumab 1pentetreotide 1olaparib 1fludarabine phosphate 1entrectinib 1dactolisib 1cabozantinib 1atezolizumab 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1alectinib 1Whole Body Imaging 1Tretinoin 1Respiratory Therapy 1Quality of Life 1Positron-Emission Tomography 1Patient Reported Outcome Measures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × lutetium Lu 177 dotatate × CNS × Clear all
NCT06607692 2026-06-04

LUPARPED

Fundación de investigación HM

Phase 1/2 Recruiting
25 enrolled
CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
130 enrolled
CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT03923257 2021-06-08

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

University of Iowa

Phase 1/2 Withdrawn
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04029428 2020-04-01

POLNETS_PRRT

University of Warmia and Mazury

Phase 2 Unknown
150 enrolled
CNSEndocrineNET

Paraganglioma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡